Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas

Expert Review of Anticancer Therapy

Volumn 12, Issue 9, 2012, Pages 1217-1228

  Chmielowski, Bartosz ^a   Federman, Noah ^a   Tap, William D ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

clinical benefit rate; clinical trial end point; mammalian target of rapamycin; overall survival; progression free survival; soft tissue sarcoma

Indexed keywords

DASATINIB; IMATINIB; PAZOPANIB; PLACEBO; RAPAMYCIN; RIDAFOROLIMUS; SORAFENIB; SUNITINIB;

ANGIOSARCOMA; CHORDOMA; CLINICAL TRIAL (TOPIC); DISSEMINATED CANCER; DRUG EFFICACY; GASTROINTESTINAL STROMAL TUMOR; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; MALIGNANT FIBROUS HISTIOCYTOMA; MESENCHYME; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RARE DISEASE; REVIEW; SARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TREATMENT RESPONSE; UNDIFFERENTIATED PLEOMORPHIC SARCOMA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DRUG SUBSTITUTION; DRUGS, INVESTIGATIONAL; ENDPOINT DETERMINATION; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PROGNOSIS; PYRIMIDINES; SARCOMA; SIROLIMUS; SULFONAMIDES; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84867934536     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.100     Document Type: Review

References (76)

1. Coindre JM, Terrier P, Guillou L et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 91(10), 1914-1926 (2001). (Pubitemid 32424119)
2. WHO. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Fletcher CDM, Unni KK, Mertens F (Eds). IARC Press, Lyon, France (2002).
3. Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases. Int. J. Cancer 119(12), 2922-2930 (2006). (Pubitemid 44846246)
4. Lurkin A, Ducimetière F, Vince DR et al. Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region. BMC Cancer 10, 150 (2010).
5. American Cancer Society. Cancer Facts & Figures 2010. American Cancer Society, Inc., Atlanta, GA, USA (2010).
6. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA. Cancer J. Clin. 59(4), 225-249 (2009).
7. Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J. Clin. Oncol. 14(5), 1679-1689 (1996). (Pubitemid 26134227)
8. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J. Clin. Oncol. 20(3), 791-796 (2002). (Pubitemid 34111387)
9. Kasper B. Standards and novel therapeutic options in the treatment of patients with soft tissue sarcoma. Rev. Recent Clin. Trials 2(3), 206-211 (2007). (Pubitemid 47558824)
10. Spira AI, Ettinger DS. The use of chemotherapy in soft-tissue sarcomas. Oncologist 7(4), 348-359 (2002). (Pubitemid 34919959)
11. Casali PG, Blay JY; ESMO/ CONTICANET/EUROBONET Consensus Panel of experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), v198-v203 (2010).
12. Van Glabbeke M, van Oosterom AT, Oosterhuis JW et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracyclinecontaining first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J. Clin. Oncol. 17(1), 150-157 (1999). (Pubitemid 29022388)
13. Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline. Sarcoma 4(3), 103-112 (2000).
14. Halpern JL, Gilbert J, Holt GE, Schwartz HS. Chemotherapy for soft tissue sarcoma. Curr. Opin. Orthop. 18(6), 604-610 (2007). (Pubitemid 350293726)
15. Longhi A, Ferrari S, Bacci G, Specchia S. Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer. Drugs 18(6), 737-744 (2007). (Pubitemid 47343670)
16. Edmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J. Clin. Oncol. 11(7), 1269-1275 (1993). (Pubitemid 23199129)
17. Santoro A, Tursz T, Mouridsen H et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 13(7), 1537-1545 (1995).
18. Le Cesne A, Judson I, Crowther D et al. Randomized Phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colonystimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 18(14), 2676-2684 (2000). (Pubitemid 30463549)
19. Fayette J, Penel N, Chevreau C et al. Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissuesarcoma. Invest. New Drugs 27(5), 482-489 (2009).
20. Pratt CB, Maurer HM, Gieser P et al. Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group study. Med. Pediatr. Oncol. 30(4), 201-209 (1998). (Pubitemid 28082444)
21. Pappo AS, Devidas M, Jenkins J et al. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J. Clin. Oncol. 23(18), 4031-4038 (2005). (Pubitemid 46211307)
22. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist 13(Suppl. 2), 19-21 (2008).
23. Schuetze SM, Baker LH, Benjamin RS, Canetta R. Selection of response criteria for clinical trials of sarcoma treatment. Oncologist 13(Suppl. 2), 32-40 (2008).
24. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305(5), 487-494 (2011).
25. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228-247 (2009).
26. Evilevitch V, Weber WA, Tap WD et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin. Cancer Res. 14(3), 715-720 (2008). (Pubitemid 351231152)
27. Ohorodnyk P, Eisenhauer EA, Booth CM. Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point? Eur. J. Cancer 45(13), 2249-2252 (2009).
28. Benz MR, Czernin J, Allen-Auerbach MS et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin. Cancer Res. 15(8), 2856-2863 (2009).
29. Young H, Baum R, Cremerius U et al. Measurement of clinical and subclinical tumour response using [18F]- fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur. J. Cancer 35(13), 1773-1782 (1999). (Pubitemid 29512308)
30. Poveda A, López-Pousa A, Martín J et al. Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX®/ Doxil®) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: a study of the Spanish Group for Research in Sarcomas (GEIS). Sarcoma 9(3-4), 127-132 (2005).
31. Schreiber D, Bell RS, Wunder JS et al. Evaluating function and health related quality of life in patients treated for extremity soft tissue sarcoma. Qual. Life Res. 15(9), 1439-1446 (2006). (Pubitemid 44736777)
32. Ginsberg JP, Rai SN, Carlson CA et al. A comparative analysis of functional outcomes in adolescents and young adults with lower-extremity bone sarcoma. Pediatr. Blood Cancer 49(7), 964-969 (2007). (Pubitemid 350022453)
33. Kotilingam D, Lev DC, Lazar AJ, Pollock RE. Staging soft tissue sarcoma: evolution and change. CA. Cancer J. Clin. 56(5), 282-291; quiz 314-315 (2006). (Pubitemid 44527490)
34. Francis P, Namløs HM, Müller C et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 8, 73 (2007).
35. Lahat G, Tuvin D, Wei C et al. Molecular prognosticators of complex karyotype soft tissue sarcoma outcome: a tissue microarray-based study. Ann. Oncol. 21(5), 1112-1120 (2010).
36. Folpe AL, Deyrup AT. Alveolar soft-part sarcoma: a review and update. J. Clin. Pathol. 59(11), 1127-1132 (2006). (Pubitemid 44787132)
37. Verweij J. Other endpoints in screening studies for soft tissue sarcomas. Oncologist 13(Suppl. 2), 27-31 (2008).
38. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J. Clin. Oncol. 22(18), 3813-3825 (2004). (Pubitemid 41095223)
39. Blanke CD, Demetri GD, von Mehren M et al. Long-term results from a randomized Phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol. 26(4), 620-625 (2008). (Pubitemid 351264357)
40. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol. 26(4), 626-632 (2008). (Pubitemid 351264358)
41. Dirnhofer S, Leyvraz S. Current standards and progress in understanding and treatment of GIST. Swiss Med. Wkly. 139(7-8), 90-102 (2009).
42. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur. J. Cancer 42(8), 1031-1039 (2006).
43. Choi H. Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr. Oncol. Rep. 7(4), 307-311 (2005). (Pubitemid 41149677)
44. Hong X, Choi H, Loyer EM, Benjamin RS, Trent JC, Charnsangavej C. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. Radiographics 26(2), 481-495 (2006). (Pubitemid 43515319)
45. Choi H, Charnsangavej C, Faria SC et al. Correlation of computed tomography and positron emission tomography in patientswith metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol. 25(13), 1753-1759 (2007). (Pubitemid 46797957)
46. Benjamin RS, Choi H, Macapinlac HA et al. We should desist using RECIST, at least in GIST. J. Clin. Oncol. 25(13), 1760-1764 (2007). (Pubitemid 46797958)
47. Le Cesne A, Van Glabbeke M, Verweij J et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG Phase III trial. J. Clin. Oncol. 27(24), 3969-3974 (2009).
48. Blay JY, Le Cesne A, Ray-Coquard I et al. Prospective multicentric randomized Phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J. Clin. Oncol. 25(9), 1107-1113 (2007). (Pubitemid 46596763)
49. Blay JY, Adenis A, Ray-Coquard I, Cassier PA, Le Cesne A. Is there a role for discontinuing imatinib in patients with advanced gastrointestinal stromal tumour? Curr. Opin. Oncol. 21(4), 360-366 (2009).
50. Ray-Coquard IL, Bin Bui N, Adenis A et al. Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: results of the prospective BFR14 randomized Phase III study comparing interruption versus continuation of IM at 5 years of treatment: a French Sarcoma Group Study. J. Clin. Oncol. 28(Suppl. 7), Abstract 10032 (2010).
51. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441(7092), 424-430 (2006). (Pubitemid 44050136)
52. Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J. Hematol. Oncol. 2, 45 (2009).
53. Hudes GR. Targeting mTOR in renal cell carcinoma. Cancer 115(Suppl. 10), 2313-2320 (2009).
54. Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist 12(8), 1007-1018 (2007). (Pubitemid 47359144)
55. Harding MW. Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy. Clin. Cancer Res. 9(8), 2882-2886 (2003). (Pubitemid 36993244)
56. Easton JB, Houghton PJ. Therapeutic potential of target of rapamycin inhibitors. Expert Opin. Ther. Targets 8(6), 551-564 (2004). (Pubitemid 40028366)
57. Hudes G, Carducci M, Tomczak P et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271-2281 (2007). (Pubitemid 46849157)
58. Motzer RJ, Escudier B, Oudard S et al. RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372(9637), 449-456 (2008).
59. Agarwala SS, Case S. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. Oncologist 15(3), 236-245 (2010).
60. Schuetze SM, Baker LH, Maki RG. Sirolimus reduced tumor-related morbidity and resulted in biochemical and radiographic response in patients with progressive sarcoma. J. Clin. Oncol. 24(Suppl. 18), Abstract 9503 (2006).
61. Chawla SP, Tolcher AW, Staddon AP et al. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of Phase II trial. J. Clin. Oncol. 25, Abstract 10076 (2007).
62. Mita MM, Britten CD, Poplin E et al. Deforolimus trial 106- A Phase I trial evaluating 7 regimens of oral Deforolimus (AP23573, MK-8669). J. Clin. Oncol. 26(Suppl.), Abstract 3509 (2008).
63. Fidias PM, Dakhil SR, Lyss AP et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 27(4), 591-598 (2009).
64. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, Phase 3 study. Lancet 374(9699), 1432-1440 (2009).
65. Cappuzzo F, Coudert B, Wierzbicki R et al. A Phase III study of erlotinib as maintenance therapy in NSCLC to delay progression following first-line chemotherapy (SATURN). Eur. J. Cancer 7, 553 (2009).
66. Chawla SP, Blay JY, Ray-Coquard IL et al. Results of the Phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J. Clin. Oncol. 29(Suppl. 15), Abstract 10005 (2011).
67. Blay JY, Chawla SP, Ray-Coquard I et al. Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: long-term (≥ 24 months) overall survival results. J. Clin. Oncol. 30(Suppl. 15), Abstract 10010 (2012).
68. Sleijfer S, Ray-Coquard I, Papai Z et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a Phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J. Clin. Oncol. 27(19), 3126-3132 (2009).
69. Sleijfer S, Van Glabbeke MM, Lamers C et al. Soluble factors (SF) associated with efficacy and toxicity of pazopanib (PZB) in advanced soft tissue sarcoma (STS) patients (pts): an EORTC-STBSG study. J. Clin. Oncol. 28(Suppl. 7), Abstract 10040 (2010).
70. van der Graaf WT, Blay JY, Chawla SP et al.; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet 379(9829), 1879-1886 (2012).
71. Chugh R, Wathen JK, Maki RG et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J. Clin. Oncol. 27(19), 3148-3153 (2009).
72. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7(10), 3129-3140 (2008).
73. Maki RG, D'Adamo DR, Keohan ML et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J. Clin. Oncol. 27(19), 3133-3140 (2009).
74. Penel N, Ray-Coquard A, Cioffi A et al. A stratified Phase II trial investigating sorafenib (SORA) in patients (pts) with metastatic or locally advanced angiosarcoma (AS). J. Clin. Oncol. 28(Suppl. 15), Abstract 10026 (2010).
75. George S, Merriam P, Maki RG et al. Multicenter Phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J. Clin. Oncol. 27(19), 3154-3160 (2009).
76. Schuetze S, Wathen K, Choy E et al. Results of a Sarcoma Alliance for Research through Collaboration (SARC) Phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma. J. Clin. Oncol. 28(Suppl. 7), Abstract 10009 (2010).